Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0027960 (
mole
)
21,279
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
This study aimed to detect in vivo expression of human
melanoma-associated antigen D-1
, which was identified by screening an expression cDNA library constructed from mRNA extracted from cultured melanoma cells with sera from patients with melanoma. The tissue distribution of
D-1 antigen
was then analyzed. Murine anti-D-1 recombinant peptide polyclonal antibodies were raised by immunization of in vitro synthesized D-1 peptide against Balb/c mice and applied immunohistochemically on paraffin-embedded tissue specimens.
D-1 antigen
was found to be restrictedly expressed on melanoma cells, but not on normal melanocytes, adjacent keratinocytes, fibroblasts, lymphocytes and adnexal structures of skin. The reactivities of anti-D-1 antibodies did not correlate with histogenesis of the lesions, their ability to produce melanin, and/or their primary or metastatic nature. There was no positive reactivity of anti-D-1 antibodies with other skin tumors, including squamous cell carcinoma, basal cell epithelioma, seborrheic keratosis, and
nevus
cell
nevus
. Further, cytoplasmic expression of
D-1 antigen
in melanoma cells was observed only in a certain subgroup of patients with melanoma. This indicates that the cell surface expression of D-1 peptide requires specific transporting proteins, such as HLA molecules.
...
PMID:Tissue distribution of a melanoma-associated antigen immunogenic in patients with melanoma as analyzed by polyclonal antibodies to recombinant peptide antigen. 893 36
A human
melanoma-associated antigen D-1
was recently identified by screening an expression cDNA library derived from mRNA of cultured melanoma cells with sera of melanoma patients. The aim of this study is to present in vivo expression and precise distribution of D-1 in normal tissues and benign or malignant neoplasms. By in situ hybridization, we found that the D-1 mRNA was exclusively expressed in the cytoplasms of melanoma cells, but not in keratinocytes, fibroblasts and lymphocytes adjacent to melanoma nests. Further immunohistochemical studies revealed that the expression of
D-1 antigen
was distributed to both the surface and cytoplasm of melanoma cells, indicating that
D-1 antigen
can be recognized by killer T lymphocytes or antibodies in vivo. No significant mRNA nor peptide of D-1 was detected in basal cell carcinoma, squamous cell carcinoma and other benign tumors such as melanocytic
nevi
and seborrheic keratosis. We also confirmed that D-1 mRNA and peptide were not expressed in normal organs by dot blot hybridization and western blot analysis, respectively. These results will assess the suitability of recombinant
D-1 protein
to implement active specific immunotherapy against melanoma.
...
PMID:Tissue distribution of a melanoma-associated antigen D-1 immunogenic in patients with melanoma. 967 93